Skip to main content
Clinical Trials/NL-OMON48115
NL-OMON48115
Completed
Not Applicable

An Observational, Prospective Multicentre Clinical Study to assess the safety and clinical performance of a New Single-use Negative Pressure Wound Therapy System (PICO 7Y) for the Simultaneous Management of Bilateral Closed Incisions in Oncoplastic Breast Surgery Patients - PICO7Y

Smith&Nephew, Inc0 sites6 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
breast cancer surgery
Sponsor
Smith&Nephew, Inc
Enrollment
6
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
Smith&Nephew, Inc

Eligibility Criteria

Inclusion Criteria

  • 1\. The subject must have understood and provided written informed consent
  • 2\. Female subjects who must be at least eighteen (18\) years of age.
  • 3\. Willing and able to make all required study visits.
  • 4\. Able to follow instructions.
  • 5\. Subjects must be undergoing, at the same time, both an oncoplastic breast
  • surgery and a symmetrising breast reduction on the contralateral breast and
  • have closed incisions that would benefit from NPWT.
  • 6\. Subjects whose incisions will fit comfortably within the area of the pad of
  • the dressing sizes provided.

Exclusion Criteria

  • 1\. Contraindications (per the PICO 7Y IFU) or hypersensitivity to the use of
  • the investigational product or their components (i.e., silicone adhesives and
  • polyurethane films \[direct contact with wound], acrylic adhesives \[direct
  • contact with skin], polyethylene fabrics and super\-absorbent powders
  • \[polyacrylates]) within the dressing.
  • 2\. Subjects with skin features (e.g. tattoos, skin colour, pre\-existing
  • scarring) which in the opinion of the Investigator, will interfere with the
  • study assessments.
  • 3\. Suspected or confirmed allergy to any of the components of the ancillary
  • products should they be deemed required, e.g. in the case of SECURA No\-sting

Outcomes

Primary Outcomes

Not specified

Similar Trials